Abstract: The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply-sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.

Abstract: A mesenchymal stem/stromal (MSC) cell line, in particular a human mesenchymal stem cell (hMSC), capable of chondrogenic differentiation when cultured in a chondrogenic medium, comprising a first transgene comprising a first nucleic acid sequence encoding for a preferably mammalian immortalizing enzyme under control of a first promoter sequence operable in said mesenchymal cell and a second transgene comprising a second nucleic acid sequence encoding a preferably mammalian bone morphogenic protein under control of a second promoter sequence operable in said mesenchymal cell.

Abstract: A magnetic field probe (1) having a capsule (3), in which an MR-active substance (5) is encapsulated. Two coils (7, 9) are preferably arranged in the capsule (3). Advantageous production methods for magnetic field probes (1) are also described, as well as advantageous uses of the magnetic field probe (1) and methods in which magnetic field probes (1) of this kind and arrangements of magnetic field probes (1) are used.

Abstract: The invention relates to a device (2) for injecting spin-polarized electrons and for reflecting light, comprising at least one lattice structure (3) having a plurality of recesses (4), wherein the lattice structure (3) is designed to reflect the light, and wherein a respective injection contact (5, 6) for injecting spin-polarized electrons is arranged in at least some of the recesses (4).

Abstract: Procedure for the detection of bitter almonds based on the processing of digital images, and a system and device associated therewith. Detection procedure and system for the automated classification of sweet and bitter almonds based on the processing of digital images. The fluorescence of the cyanogenic compounds naturally present in almonds generates a clear difference in colour between sweet and bitter almonds which subsequently is analysed and classified by means of a computer program. The invention also includes the device, either portable or automatic, for carrying out the classification of bitter or sweet almonds. This device will be necessary during the goods reception process and in the validation/verification of the quality of the finished product, prior to the loading and transport process.

Abstract: An organometallic compound represented by Formula 1 wherein, M1 to M4 are each independently a first-row transition metal, a second-row transition metal, or a third-row transition metal; X1 and X2 are each independently C(R5)(R6), Si(R5)(R6), N(R5), O, S, Se, or Te; W1 to W4 are each independently N(R7)(R8), P(R7)(R8), S(R7), a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a; L1 to L6 are each independently a C1-C30 alkylene group unsubstituted or substituted with at least one R10a, a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a3 to a6 are each independently an integer from 0 to 3, and R1 to R8 and R10a in Formula 1 are as described herein.

Abstract: The invention provides oligonucleotide and/or oligonucleotide analogue molecules that are antagonists of a microRNA, preferably antagonists of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, that comprise a mixture of phosphorothioate and phosphodiester linkages, and that are conjugated to at least one oleic acid molecule. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2. The present invention further provides compositions comprising said oligonucleotides and/or oligonucleotide analogue molecules and their uses for the treatment and prevention of DM in a subject in need thereof.

Abstract: Methods for processing a crude oil feedstock include introducing a crude oil stream to a reactive distillation unit to remove conradson carbon and metals from the crude oil stream and generate a distillate stream having a mean boiling point distribution less than the crude oil stream and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX. The catalytic cracking reactor includes a cracking catalyst and a susceptor material dispersed throughout the catalytic cracking reactor. Further, the catalytic cracking reactor operates at a temperature of 300° C. to 800° C. with heating from magnetic induction of the susceptor material.

Abstract: The invention relates to a computer program that when executed on a computer causes a system to execute a method, particularly a computer-implemented method for determining a plurality of functional ocular parameters, with the system comprising an optical system (3) with a display system (4) that is configured to independently project a visual stimulus to a left and a right eye of a test person, an eye-tracking system (5) configured to record a gaze direction (100) and a pupil size (102) of the left as well as the right eye, said computer (2) being configured to control the optical system (3) and to receive recorded data from the eye-tracking system (5), wherein an afferent pupillary defect (APD), particularly a relative afferent pupillary defect (RAPD) is determined from a first trial session consisting of a sequence of first kind of stimuli presented to the left and the right eye of the test person eyes with the display system (4), and wherein a visual field (400) is determined from a second trial session c

Abstract: The present invention relates to an anti-CD47 antibody or an antigen-binding fragment thereof, comprising variable heavy chain complementarity determining regions 1 to 3 (CDRH1, CDRH2, CDRH3) and variable light chain complementarity determining regions 1 to 3 (CDRL1, CDRL2, CDRL3). The anti-CD47 antibody or an antigen-binding fragment thereof is capable of blocking the interaction of CD47 with signal regulatory protein alpha (SIRPalpha). Further envisaged is an anti-CD47 antibody or antigen-binding fragment combined to a further functional component.

Abstract: The invention relates to an aluminum secondary battery comprising at least one positive electrode, at least one negative electrode, at least one electrolyte, and at least one additive, the electrolyte comprising at least one room temperature ionic liquid (RTIL), made of at least one organic salt and at least one first aluminum salt, and/or at least one deep eutectic solvent (DES) made of at least one organic solvent and at least one first aluminum salt, the additive containing bivalent metal cations and/or being suitable for forming bivalent metal cations.

Abstract: Methods for processing a crude oil feedstock include introducing a crude oil stream to a reactive distillation unit to remove conradson carbon and metals from the crude oil stream and generate a distillate stream having a mean boiling point distribution less than the crude oil stream and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor operating at a temperature of 300° C. to 800° C. with a cracking catalyst disposed therein that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX.

Abstract: The invention relates to a radial blood pump (1) for supporting a blood flow (106) in a human or animal heart (205) comprising a first and a second inlet channel (41, 42), a first outlet channel (51, 52), a first electric motor (71) comprising a first stator (77) and a first internal rotor (75), wherein the first electric motor (71) is configured to drive an impeller (2, 2a, 2b) arranged at an intersection of the first with the second inlet channel (41, 42), wherein the impeller (2, 2a, 2b) is connected to the first internal rotor (75) and wherein the impeller (2, 2a, 2b) comprises a merging portion (22) arranged at the intersection, where a merging of a first blood flow (106) coming from the first inlet channel (41) and a second blood flow (107) coming from the second inlet channel (42) takes place, wherein the impeller (2, 2a, 2b) is configured to pump the first and second blood flow (106, 107) from the first and second inlet channel (41, 42) via the merging portion (22) to the first outlet channel (51), a

Abstract: An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.

Abstract: Therapeutic compounds of the invention comprise peptidomimetics, including those of formula (I), which has been prepared using solid-phase peptide synthesis. It is useful in the treatment of a cancer, including, for the treatment of a pancreatic cancer, a lung cancer or a colorectal cancer, further, including, a treatment for a pancreatic ductal adenocarcinoma.

Abstract: The present invention relates to a pharmaceutical nucleic acid agent capable of downregulating or inhibiting the activity of the minor spliceosome (MiS) for use in treatment or prevention of recurrence of cancer. The invention also relates to a method for the diagnosis of cancer.

Abstract: The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient. The invention also relates to the field of antigen specific immunotherapies, such as the induction of tolerance.

Abstract: The present invention provides an isolated protein exhibiting an antiaggregating activity and/or disaggregating activity toward a target protein comprising an extended polyQ stretch. The protein comprises a Zn2+-binding region, wherein the conserved motif is HxxEHx75-80E and x is any amino acid. The nucleic acid construct encoding said protein as well as the corresponding mRNA sequence are also provided. The protein, the nucleic acid construct or mRNA sequence are for use in a method for prevention or treatment of a neurodegenerative disease that is caused by aggregates comprising at least one target protein and/or by the mRNA encoding for said target protein, wherein the target protein causes e.g. Huntington's disease or Machado-Joseph disease.

Abstract: A method (500) for conditioning or hydrolysis of an extruded membrane is disclosed. The method (500) comprising ion exchange processes in divided electrochemical cells using a cation exchanger membrane. The method (500) includes extruding the perfluorosulfonyl fluoride membranes from perfluorosulfonyl fluoride granulate. The method (500) also includes using a pretreatment technique to increase the ionic conductivity of the extruded perfluorosulfonyl fluoride membranes before using the perfluorosulfonic acid membranes in electrolysis cells. The method (500) also includes applying a milder pretreatment technique by activating S—F bonds to execute nucleophilic exchange of the fluoride group in a reaction. The method (500) also includes hydrolyzing sulfonyl fluoride groups to sulfonic acid using triethylsilanol.

Abstract: A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 ?M to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.